Yeasen Launches UltraAAV Transfection Reagent Tailored for AAV Gene Therapy Development and Commercial Manufacturing
Yeasen
Tool Enzyme Raw Materials and Diagnostic Product R&D, Manufacturer
01
Exhibitor Promotion
Abbreviation:Yeasen
Booth No.: A04
Yisheng Biotechnology (Shanghai) Co., Ltd. is a company focused on core raw materials in the upstream segment of the life science industry chain,A high-tech enterprise engaged in the research and development, production, and sales of four major categories of biological reagents: nucleotides, proteins, cells, and organoids.. Core products cover the qPCR series,NGSreverse transcription series, nucleic acid extraction and purification series, PCR series, molecular cloning series, in vitro transcription series, antibodies, protein purification series, protein analysis series, recombinant proteins, cell analysis series, cell culture series, cell transfection series, reporter gene assay series, organoids, and other product categories, which are widely used in life science research, diagnostic testing, biopharmaceuticals, and other fields.
02
Product Introduction
In cell and gene therapy (In the field of cell and gene therapy (CGT), the efficient production of adeno-associated virus (AAV) vectors has long been one of the industry’s key challenges. Traditional transfection reagents often encounter issues such as high costs and difficulties in process scale-up during large-scale manufacturing. However, UltraAAV Transfection Reagent offers innovative solutions to these problems by leveraging its unique technological advantages.
Yeasen's Independently Developed NovelUltraAAV Transfection Reagent, specifically developed for scalable production of recombinant AAV in suspension 293 cell lines, achieves unchanged viral yield with half the reagent dosage; furthermore, both viral yield and full-to-empty capsid ratio are significantly superior to those of Brand P transfection reagent.UltraAAV transfection reagent not only improves production efficiency but also reduces production costs, which is crucial for the future development of CGT drugs. Cost reduction and efficiency enhancement have become a major trend in the future development of CGT drugs, and Yeasen’s products precisely meet this market demand.
Figure1. UltraAAV Transfection Reagent DMF Filing Number
Yeasen'sHieff Trans® Transfection Reagent R&D PlatformWith a “trinity” architecture of AI-driven molecular design, high-throughput validation, and compliant quality control, PingThe platform has given rise to star reagents such as UltraAAV, achieving a viral yield of E12 VG/mL with half the dosage, via FDA DMF filing, supporting dual submissions in China and the US, has become a core tool for domestic substitution and global expansion; the key features of the novel transfection reagent are mainly as follows:
Figure2. Screening of Molecules Modified with Hieff Trans® Novel Transfection Reagent
Maintain high titers while halving the amount of transfection reagent
Figure3 Comparison of the Efficacy Between a Novel Transfection Reagent and Company P’s Transfection Reagent
Reliable Quality, Complete Qualifications, Worry-Free Project Application
1. CompliantRegulatoryGMPProduction Base
●Built in WuhanGMP-compliant manufacturing facility with a total area of nearly 10,000 square meters and an annual production capacity exceeding 10,000 liters, capable of meeting global commercial demand.
●Production Workshop CompliancecGMP and ISO 13485 standards, modular design, supporting flexible capacity expansion and customizationMass Production, to meet the audit requirements for China-U.S. projects.
2. Rigorous Quality Control System
●Establishment“Raw Material–Process–Finished Product” Three-Tier Quality Control Standards Ensure Stable Product Manufacturing.
●Implementation of Process Analytical Technology for MonitoringCore indicators such as PEI molecular weight distribution and charge density are controlled to minimize batch-to-batch variations.
3. Closed-Loop Domestic Supply Chain
●Key raw materials such as high-purityPolyethylenimine, functional modification reagents have all achieved domestic substitution.
●The logistics network covers China,24-Hour Rapid Response to Ensure Customers Experience “No Supply Interruptions, No Waiting.”
Product Information
Contact Us
Tel: 400-6111-883
Domestic: marketing@yeasen.com
Overseas: overseas@yeasen.com
Address: Lane 166, Tianxiong Road, Pudong New Area, Shanghai1Room 402, Building [Number]
Scan the QR code to follow Yeasen's official WeChat account
2025 CSGCT Conference
To drive technological breakthroughs, industrial integration, policy alignment, and international cooperation in China’s cell and gene therapy (CGT) sector, and to propel the Chinese CGT industry to the forefront of global competition, the China Society for Gene and Cell Therapy (CSGCT) Conference was established.
Leveraging its close ties with the ASGCT (American Society of Gene & Cell Therapy), the 2025 CSGCT Annual Meeting will bring togetherGlobal Excellence in Sciencefamilies, clinical experts, multinational pharmaceutical companies, and overseas investment institutions, bringing the mostCutting-edge research advancements, technologies and applications, market access information, high-quality collaboration projects, and overseas investors and investment opportunitiesSeeking Collaboration: Building a Platform for In-Depth Exchange and Cooperation between China’s Cell and Gene Therapy Industry and the Global Industrial Chain.
The conference closely addressed the industry’s hotspots, pain points, and bottlenecks, featuring1 Main Forum + 15 High-End Sub-Forums, coveringLatest advances in global gene therapy, immune cell therapy, in vivo CAR-T, adult stem cells and exosomes, iPSC-derived cell therapies, small nucleic acid drugs, gene editing, oncolytic viruses, and tumor vaccines, as well as CMC and testing, AI-driven drug discovery, registration and regulation, and financing and BD matchmakingWaitComprehensive coverage of the entire industry chain.
2025 2nd China Society for Gene and Cell Therapy (CSGCT) Conference
September 12–13, 2025
Zhongguancun National Independent Innovation Demonstration Zone Exhibition and Trading Center [Conference Center]
For more details, please scan the QR code to visit the official conference website.
Special Planning for the 2nd China Society of Gene and Cell Therapy (CSGCT) Conference in 2025“2025 CSGCT Conference Project Pitch” Session, bringing together over 1,000 high-quality domestic and international investment institutions, industrial investors, and decision-makers from government industrial guidance funds; attracting multinational corporations (MNCs) as well as renowned domestic and international medical and pharmaceutical companies seeking business development (BD) collaborations with outstanding projects, products, and technologies; and accelerating the exchange and cooperation on the most distinctive new technologies, new products, and new ecosystems in China’s cell and gene therapy (CGT) sector.
Conference Forum Details
Inquiries for Speaking/Sponsorship/Exhibition and Business Cooperation
Ms. Li: 18600921680 (WeChat ID same as phone number)
Conference Registration / Business Delegation Inquiry
Ms. Ren: 15111945514 (WeChat)